Lazertinib (Leclaza): 3rd Gen EGFR Inhibitor for NSCLC
Lazertinib is a potent, third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI). It is designed to target both the activating EGFR mutations (Exon 19 del, L858R) and the T790M resistance mutation, while sparing wild-type EGFR.
Lazertinib (Leclaza) is highly brain-penetrant, offering efficacy specifically against central nervous system (CNS) metastases in lung cancer patients. It serves as a critical option for patients who have developed resistance to earlier treatments.
Recently, it has gained attention for its potential use in combination therapies (e.g., with amivantamab) to further improve survival rates.
Indications
- EGFR-mutated NSCLC: Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with sensitive EGFR mutations.
- T790M Positive: Specifically indicated for patients whose disease has progressed on or after prior EGFR TKI therapy and who have developed the T790M mutation.
Dosage and administration
Consistency is key for maintaining therapeutic blood levels.
- Standard Dose: 240 mg administered orally once daily. (Typically three 80 mg tablets).
- Administration: Swallow tablets whole with water. Can be taken with or without food. Administer at the same time each day.
- Missed Dose: If a dose is missed, take it as soon as remembered unless it is within 12 hours of the next dose.
- Interstitial Lung Disease (ILD): Contraindicated in patients with acute ILD or a history of severe ILD/pneumonitis.
- Pregnancy and Breastfeeding.
- Severe hypersensitivity to lazertinib.
Sensory and dermatological effects are common.
- Paresthesia: Tingling or numbness in extremities (hands/feet) is a notable side effect.
- Dermatologic: Rash, pruritus (itching), dry skin.
- Musculoskeletal: Muscle pain, joint pain.
- Metabolic: Decreased appetite, hypoalbuminemia.
List of medicines by active substance Lazertinib
✅ All products loaded (1)